Press releases

Stay up to date with our activities by browsing our press releases and company presentations below.

Press Material


Logotype


Patric Stenberg, CEO

+46 (0)733 83 66 70
patric.stenberg@gesynta.se 

Learn more about Gesynta Pharma

Gesynta Pharma bases its R&D on groundbreaking research from the Karolinska Institutet.

Our executive team and board of directors hold vast experience in drug development, commercialization and company scale-up.

Endometriosis is a chronic, inflammatory, estrogen-dependent disease affecting millions of women worldwide.

Our lead drug candidate vipoglanstat is in clinical phase II, while GS-073 is ready to enter clinical phase I.